ArticleFrontiers in oncology2026
Methylation profiling reveals epigenetic programs associated with chr18 loss in small intestinal neuroendocrine tumors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are characterized by a low mutational burden and limited recurrent driver mutations, suggesting that other mechanisms contribute to tumor development. One of the most frequent genomic alterations in SI-NETs is loss of heterozygosity on chromosome 18 (chr18del), which defines a major molecular subtype. However, the epigenetic consequences of this event remain poorly understood. Methods: In this study, we used long-read whole-genome sequencing to characterize genome-wide DNA methylation patterns in twelve primary tumors. Native methylation detection and copy-number profiling enabled stratification of tumors according to chromosome 18 status and direct comparison of epigenetic states between chr18del and non-chr18del (diploid) tumors. Results: Chr18del tumors displayed widespread hypomethylation relative to diploid tumors, while chromosome 18 showed spatially structured regional methylation differences, including localized regions of increased methylation. Cross-platform validation using an independent Illumina EPIC methylation cohort confirmed the direction and distribution of many methylation events. Integration with the corresponding transcriptomic dataset revealed that a subset of methylation changes was associated with differential gene expression consistent with established promoter- and gene-body methylation models. Functional categorization of these methylation states revealed regulatory patterns linked to neuronal signaling, intracellular signaling cascades, and interactions with the extracellular matrix. Discussion: Together, these findings support an association between chromosome 18 status and widespread methylation differences that extend beyond the affected chromosome and are linked to transcriptional programs relevant to neuroendocrine tumor biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.